Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
Authors
Keywords
-
Journal
BMC CANCER
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-24
DOI
10.1186/s12885-021-08031-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
- (2020) Eva Versteijne et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
- (2020) Quisette P. Janssen et al. Frontiers in Oncology
- Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
- (2020) Jordan M. Cloyd et al. Journal of Clinical Medicine
- A contemporary analysis of palliative procedures in aborted pancreatoduodenectomy: Morbidity, mortality, and impact on future therapy
- (2020) Feredun S. Azari et al. SURGERY
- Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis
- (2019) Quisette P Janssen et al. JNCI-Journal of the National Cancer Institute
- Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer
- (2018) Jin-Young Jang et al. ANNALS OF SURGERY
- Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
- (2018) E. Versteijne et al. BRITISH JOURNAL OF SURGERY
- Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial.
- (2018) Geertjan Van Tienhoven et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After
- (2017) Claudio Bassi et al. SURGERY
- Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival
- (2016) Sun Mi Lee et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
- (2016) Mustafa Suker et al. LANCET ONCOLOGY
- Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial
- (2016) Eva Versteijne et al. Trials
- Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma
- (2015) Alessandro Paniccia et al. JAMA Surgery
- Postoperative Complications Reduce Adjuvant Chemotherapy Use in Resectable Pancreatic Cancer
- (2013) Ryan P. Merkow et al. ANNALS OF SURGERY
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Management of Patients with Pancreatic Adenocarcinoma: National Trends in Patient Selection, Operative Management, and Use of Adjuvant Therapy
- (2011) Skye C. Mayo et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
- (2010) John P. Neoptolemos et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study
- (2008) B. Chauffert et al. ANNALS OF ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search